STATE OF NEW YORK

649--A

2021-2022 Regular Sessions

IN SENATE

(Prefiled)

January 6, 2021

Introduced by Sen. HARCKHAM -- read twice and ordered printed, and when printed to be committed to the Committee on Health -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the social services law and the public health law, in relation to medication for the treatment of substance use disorders

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

1 Section 1. Subdivision 2 of section 365-a of the social services law 2 is amended by adding a new paragraph (gg) to read as follows: 3 (gg) all buprenorphine products, methadone or long acting injectable 4 naltrexone for detoxification or maintenance treatment of a substance 5 use disorder prescribed according to generally accepted national profes-6 sional guidelines for the treatment of a substance use disorder. Such 7 medication assisted treatment shall not be subject to any prior authori-8 zation mandate. § 2. Subdivision 26-b of section 364-j of the social services law, as 9 10 added by section 4 of part B of chapter 69 of the laws of 2016, is 11 amended to read as follows: 26-b. Managed care providers shall not require prior authorization for 12 13 [an initial or renewal prescription for buprenorphine or injectable naltrexone for detoxification or maintenance treatment of opioid 14 addiction unless the prescription is for a non-preferred or non-formu-15 16 lary form of the drug or as otherwise required by section 1927(k)(6) of 17 the social Security Act] any buprenorphine products, methadone or long 18 acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder prescribed according to generally accepted 19 20 national professional guidelines for the treatment of a substance use 21 <u>disorder</u>.

EXPLANATION--Matter in <u>italics</u> (underscored) is new; matter in brackets [-] is old law to be omitted.

LBD00371-03-1

1 § 3. Subdivision 10 of section 273 of the public health law, as amended by section 7 of part GG of chapter 56 of the laws of 2020, is 2 amended to read as follows: 3 4 10. Prior authorization shall not be required for [an initial or 5 renewal prescription for buprenorphine or injectable naltrexone for detoxification or maintenance treatment of opioid addiction unless the б 7 prescription is for a non-preferred or non-formulary form of such drug 8 as otherwise required by section 1927(k)(6) of the Social Security Act. Further, prior authorization shall not be required for] any buprenor-9 10 phine products, methadone, [when used for opioid use disorder and admin-11 istered or dispensed in an opioid treatment program] or long acting 12 injectable naltrexone for detoxification or maintenance treatment of a 13 substance use disorder prescribed according to generally accepted 14 national professional guidelines for the treatment of a substance use <u>disorder</u>. 15 16 § 4. This act shall take effect on the ninetieth day after it shall

have become a law; provided, however, that the amendments to subdivision 18 26-b of section 364-j of the social services law made by section two of 19 this act shall not affect the repeal of such section, and shall be 20 deemed repealed therewith.